Your browser doesn't support javascript.
loading
Validation of Patras Immunotherapy Score model for prediction and prognosis of patients with advanced NSCLC treated with nivolumab or pembrolizumab: results from a European multicentre study.
Dimitrakopoulos, Foteinos-Ioannis; Mountzios, Giannis; Christopoulos, Petros; Papastergiou, Thomas; Elshiaty, Mariam; Daniello, Lea; Zervas, Elefterios; Agelaki, Sofia; Samantas, Epaminondas; Nikolaidi, Adamantia; Athanasiadis, Ilias; Baka, Sofia; Syrigos, Konstantinos; Christopoulou, Athina; Lianos, Evangelos; Samitas, Konstantinos; Tsoukalas, Nikolaos; Perdikouri, Eleni-Isidora; Oikonomopoulos, George; Kottorou, Anastasia; Kalofonou, Foteini; Makatsoris, Thomas; Koutras, Angelos; Megalooikonomou, Vasileios; Kalofonos, Haralabos.
Afiliación
  • Dimitrakopoulos FI; Division of Oncology, Department of Medicine, University Hospital of Patras, Patras, GreeceMolecular Oncology Laboratory, Department of Medicine, University of Patras, Patras, Greece.
  • Mountzios G; Second Department of Medical Oncology and Clinical Trials Unit, Henry Dunant Hospital Center, Athens, Greece.
  • Christopoulos P; Department of Thoracic Oncology, Thoraxklinik at Heidelberg University Hospital, Heidelberg, GermanyTranslational Lung Research Center Heidelberg, Heidelberg, Germany.
  • Papastergiou T; Computer Engineering and Informatics Department, University of Patras, Patras, Greece.
  • Elshiaty M; Department of Thoracic Oncology, Thoraxklinik at Heidelberg University Hospital, Heidelberg, GermanyTranslational Lung Research Center Heidelberg, Heidelberg, Germany.
  • Daniello L; Department of Thoracic Oncology, Thoraxklinik at Heidelberg University Hospital, Heidelberg, GermanyTranslational Lung Research Center Heidelberg, Heidelberg, Germany.
  • Zervas E; Seventh Respiratory Medicine Department and Asthma Center, Athens Chest Hospital Sotiria, Athens, Greece.
  • Agelaki S; Department of Medical Oncology, University General Hospital, Heraklion, Greece.
  • Samantas E; Third Department of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece.
  • Nikolaidi A; Department of Medical Oncology, Mitera Hospital, Athens, Greece.
  • Athanasiadis I; Department of Medical Oncology, Mitera Hospital, Athens, Greece.
  • Baka S; Oncology Department, Interbalkan European Medical Center, Thessaloniki, Greece.
  • Syrigos K; Oncology Unit, The Third Department of Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Christopoulou A; Medical Oncology Unit, S. Andrew Hospital, Patras, Greece.
  • Lianos E; Division of Medical Oncology and Hematopoietic Cell Transplant Unit, Department of Medicine, "Metaxa" Cancer Hospital, Piraeus, Greece.
  • Samitas K; Seventh Respiratory Medicine Department and Asthma Center, Athens Chest Hospital Sotiria, Athens, Greece.
  • Tsoukalas N; Medical Oncology Unit, Veterans (NIMTS) Hospital, Athens, Greece.
  • Perdikouri EI; Oncology Department, General Hospital of Volos, Volos, Greece.
  • Oikonomopoulos G; Second Department of Medical Oncology, Metropolitan Hospital, Piraeus, Greece.
  • Kottorou A; Division of Oncology, Department of Medicine, University Hospital of Patras, Patras, GreeceMolecular Oncology Laboratory, Department of Medicine, University of Patras, Patras, Greece.
  • Kalofonou F; Department of Oncology, Imperial College NHS Healthcare Trust, Charing Cross Hospital, London, UK.
  • Makatsoris T; Division of Oncology, Department of Medicine, University Hospital of Patras, Patras, GreeceMolecular Oncology Laboratory, Department of Medicine, University of Patras, Patras, Greece.
  • Koutras A; Division of Oncology, Department of Medicine, University Hospital of Patras, Patras, GreeceMolecular Oncology Laboratory, Department of Medicine, University of Patras, Patras, Greece.
  • Megalooikonomou V; Computer Engineering and Informatics Department, University of Patras, Patras, Greece.
  • Kalofonos H; Division of Oncology, Department of Medicine, University Hospital of Patras, GreeceMolecular Oncology Laboratory, Department of Medicine, University of Patras, Rion-Patras, Patras, Achaia 26504, Greece.
Ther Adv Med Oncol ; 14: 17588359221122728, 2022.
Article en En | MEDLINE | ID: mdl-36105886
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Ther Adv Med Oncol Año: 2022 Tipo del documento: Article País de afiliación: Grecia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Ther Adv Med Oncol Año: 2022 Tipo del documento: Article País de afiliación: Grecia Pais de publicación: Reino Unido